Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

CASEY E TURNER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1083621247
CMS profile
49349
Location
CANTON, GA

General Payments · PY2018–2024

$1,881.35

  • Reported across 115 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$256.12

15 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $256.12 15

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $101.60 6
GlaxoSmithKline, LLC. $59.25 3
Novo Nordisk AS $50.60 3
Phathom Pharmaceuticals, Inc. $31.09 2
Exact Sciences Corporation $13.58 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $431.75 29
PY2019 $535.94 35
PY2020 $55.74 3
PY2022 $280.75 14
PY2023 $321.05 19
PY2024 $256.12 15

Payment records · PY2024 (15)

Sorted by paying entity, then date · as published by CMS

Program year 2024 20182019202020222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Amgen Inc. $16.66 01/22/2024 Food and Beverage Undisputed 01/23/2026 1117403262 CMS
Amgen Inc. $22.35 03/28/2024 Food and Beverage Undisputed 01/23/2026 1111729211 CMS
Amgen Inc. $14.43 06/10/2024 Food and Beverage Undisputed 01/23/2026 1117403264 CMS
Amgen Inc. $13.55 10/07/2024 Food and Beverage Undisputed 01/23/2026 1111729213 CMS
Amgen Inc. $18.32 11/18/2024 Food and Beverage Undisputed 01/23/2026 1117403266 CMS
Amgen Inc. $16.29 12/09/2024 Food and Beverage Undisputed 01/23/2026 1111729215 CMS
Exact Sciences Corporation $13.58 08/15/2024 Food and Beverage Undisputed 01/23/2026 1114936604 CMS
GlaxoSmithKline, LLC. $25.01 03/11/2024 Food and Beverage Undisputed 01/23/2026 1116298870 CMS
GlaxoSmithKline, LLC. $15.06 04/27/2024 Food and Beverage Undisputed 01/23/2026 1116477438 CMS
GlaxoSmithKline, LLC. $19.18 06/22/2024 Food and Beverage Undisputed 01/23/2026 1116338773 CMS
Novo Nordisk Inc $18.48 01/29/2024 Food and Beverage Undisputed 01/23/2026 1097832433 CMS
Novo Nordisk Inc $15.97 05/14/2024 Food and Beverage Undisputed 01/23/2026 1097355492 CMS
Novo Nordisk Inc $16.15 07/22/2024 Food and Beverage Undisputed 01/23/2026 1097524132 CMS
Phathom Pharmaceuticals, Inc. $15.51 04/23/2024 Food and Beverage Undisputed 01/23/2026 1151134792 CMS
Phathom Pharmaceuticals, Inc. $15.58 06/17/2024 Food and Beverage Undisputed 01/23/2026 1151134794 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.